Brokerages Anticipate Nabriva Therapeutics plc (NASDAQ:NBRV) Will Post Earnings of -$0.19 Per Share

Wall Street analysts expect that Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) will announce ($0.19) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Nabriva Therapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.20). Nabriva Therapeutics reported earnings per share of ($0.53) during the same quarter last year, which would indicate a positive year over year growth rate of 64.2%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Nabriva Therapeutics will report full-year earnings of ($0.67) per share for the current fiscal year, with EPS estimates ranging from ($0.73) to ($0.61). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.34) per share, with EPS estimates ranging from ($0.35) to ($0.33). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last announced its quarterly earnings data on Tuesday, March 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05). Nabriva Therapeutics had a negative return on equity of 82.13% and a negative net margin of 171.14%. During the same period in the previous year, the company posted ($1.11) EPS.

Several equities research analysts recently issued reports on NBRV shares. Northland Securities cut their price objective on Nabriva Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Wednesday, March 30th. Zacks Investment Research cut Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th. Finally, StockNews.com began coverage on Nabriva Therapeutics in a research report on Monday, April 4th. They set a “hold” rating for the company.

Several hedge funds have recently modified their holdings of NBRV. Advisor Group Holdings Inc. grew its holdings in shares of Nabriva Therapeutics by 5,200.0% in the 3rd quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 26,000 shares during the period. Millennium Management LLC purchased a new stake in shares of Nabriva Therapeutics during the 2nd quarter valued at about $42,000. Two Sigma Securities LLC purchased a new stake in Nabriva Therapeutics during the 3rd quarter worth approximately $48,000. Geode Capital Management LLC grew its position in shares of Nabriva Therapeutics by 102.9% in the 3rd quarter. Geode Capital Management LLC now owns 42,738 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 21,672 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in shares of Nabriva Therapeutics by 144.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 41,079 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 24,300 shares in the last quarter. 1.36% of the stock is owned by institutional investors and hedge funds.

NASDAQ:NBRV traded down $0.01 on Monday, reaching $0.38. The company’s stock had a trading volume of 343,169 shares, compared to its average volume of 436,921. Nabriva Therapeutics has a 12-month low of $0.37 and a 12-month high of $2.32. The company has a quick ratio of 2.94, a current ratio of 3.59 and a debt-to-equity ratio of 0.08. The firm has a market cap of $204.77 million, a price-to-earnings ratio of -0.30 and a beta of 1.55. The stock has a 50 day moving average price of $0.46 and a 200 day moving average price of $0.72.

Nabriva Therapeutics Company Profile (Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Featured Stories

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.